These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23159171)

  • 21. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
    Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Zhao L; Gong J; Qi Q; Liu C; Su H; Xing Y; Zhao J
    Int J Nanomedicine; 2023; 18():1915-1925. PubMed ID: 37064291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Observations on the Effects of Residualization and Dehalogenation on the Utility of
    Chitneni SK; Koumarianou E; Vaidyanathan G; Zalutsky MR
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31671554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
    Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V
    FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.
    Feng Y; Sarrett SM; Meshaw RL; Vaidyanathan G; Cornejo MA; Zeglis BM; Zalutsky MR
    J Med Chem; 2022 Nov; 65(22):15358-15373. PubMed ID: 36368007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
    Razumienko E; Dryden L; Scollard D; Reilly RM
    Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Labeling a TCO-functionalized single domain antibody fragment with
    Zhou Z; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours.
    Debie P; Lafont C; Defrise M; Hansen I; van Willigen DM; van Leeuwen FWB; Gijsbers R; D'Huyvetter M; Devoogdt N; Lahoutte T; Mollard P; Hernot S
    J Control Release; 2020 Jan; 317():34-42. PubMed ID: 31734445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of an
    Feng Y; Meshaw R; McDougald D; Zhou Z; Zhao XG; Jannetti SA; Reiman RE; Pippen E; Marjoram R; Schaal JL; Vaidyanathan G; Zalutsky MR
    Sci Rep; 2022 Feb; 12(1):3020. PubMed ID: 35194100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
    Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
    J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies.
    Hrynchak I; Santos L; Falcão A; Gomes CM; Abrunhosa AJ
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
    Tsai SW; Sun Y; Williams LE; Raubitschek AA; Wu AM; Shively JE
    Bioconjug Chem; 2000; 11(3):327-34. PubMed ID: 10821648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.